# Travere Therapeutics (TVTX) — News

TVTX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/tvtx/news

## Recent headlines

- [Traverre Therapeutics, - Receives USPTO notice of allowance for Filspari patent in FSGS](https://www.ainvest.com/news/traverre-therapeutics-receives-uspto-notice-allowance-filspari-patent-fsgs-2609) — AInvest Wire, Sep 23, 2026
  Travere Therapeutics, Inc. (Nasdaq: TVTX) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 19/253,088, titled “Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders.” The patent application…
- [Traverre Therapeutics announces planned chief executive officer transition](https://www.ainvest.com/news/traverre-therapeutics-announces-planned-chief-executive-officer-transition-2609) — AInvest Wire, Sep 21, 2026
  Travere Therapeutics, Inc. (Nasdaq: TVTX) has announced that William Rote, Ph.D., its chief research officer, plans to retire in February 2027, following a decade of service . Dr. Rote has played a pivotal role in advancing the company’s research and development capabilities, contributing to key…
- [Traverse Therapeutics, Inc.: TD Cowen raises target price to $75 from $60](https://www.ainvest.com/news/traverse-therapeutics-td-cowen-raises-target-price-75-60-2608) — AInvest Wire, Aug 5, 2026
  Travere Therapeutics, Inc. (TVTX) has recently seen an upward revision in its price target from TD Cowen, which raised its forecast to $75 per share from a previous $60. This adjustment reflects the firm's updated assessment of the company's growth potential and market positioning. TVTX, a…
- [Traverse Therapeutics Q2 EPS USD -0.37](https://www.ainvest.com/news/traverse-therapeutics-q2-eps-usd-0-37-2608) — AInvest Wire, Aug 4, 2026
  Travere Therapeutics reported net loss per share of -$0.37 for the second quarter of 2023. The company’s financial results reflect ongoing operational and research expenditures associated with its therapeutic development programs. As of the second quarter, the company continued to allocate…
- [Traverse Therapeutics enters into exclusive licensing agreement with Everest Medicines for CIVOREBRUTINIB a potential best-in-class BTK inhibitor for rare kidney diseases](https://www.ainvest.com/news/traverse-therapeutics-enters-exclusive-licensing-agreement-everest-medicines-civorebrutinib-potential-class-btk-inhibitor-rare-kidney-diseases-2606) — AInvest Wire, Jun 2, 2026
  Travere Therapeutics (NASDAQ: TVTX) has entered into an exclusive licensing agreement with Everest Medicines for CIVOREBRUTINIB, a potential best-in-class Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of rare kidney diseases. Under the terms of the agreement, Travere will receive an…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).